EP
RVMD icon

Edgestream Partners’s Revolution Medicines RVMD Stock Holding History

Edgestream Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
5,907
-63,355
-91% -$9.25M 0.03% 653
2026
Q1 		$6.74M Buy
+69,262
New +$6.99M 0.22% 143
2025
Q3 		– Sell
-204,313
Closed -$7.52M – 1034
2025
Q2 		$7.52M Sell
204,313
-11,404
-5% -$438K 0.21% 167
2025
Q1 		$7.63M Buy
215,717
+207,938
+2,673% +$8.44M 0.26% 101
2024
Q4 		$340K Sell
7,779
-30,703
-80% -$1.55M 0.01% 742
2024
Q3 		$1.75M Buy
+38,482
New +$1.68M 0.08% 443

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Edgestream Partners's RVMD Position: Q2 2026 in Review

Edgestream Partners reduced its Revolution Medicines (RVMD) stake by 91% in Q2 2026, selling an estimated $9.25M and leaving 5,907 shares worth $1.11M. The position accounts for 0.03% of the portfolio, ranked #653.

Edgestream Partners first reported a position in RVMD in Q3 2024 and has held it in 6 quarters since. The position peaked at $7.63M in Q1 2025. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Edgestream Partners held 5,907 shares of Revolution Medicines worth $1.11M as of Q2 2026.
  • Edgestream Partners sold 63,355 Revolution Medicines shares in Q2 2026, an estimated $9.25M.
  • Revolution Medicines made up 0.03% of Edgestream Partners's portfolio in Q2 2026, its #653 holding.
  • Edgestream Partners first reported a position in Revolution Medicines in Q3 2024 and has held it in 6 quarters since.
  • Edgestream Partners's Revolution Medicines position peaked at $7.63M in Q1 2025.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.